|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.32 SEK | +1.97% |
|
-1.89% | +28.02% |
| May. 15 | SenzaGen AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 25 | Senzagen Receives Follow-Up Order Worth SEK 0.8 Million from the Global Chemicals Leader | CI |
SenzaGen AB provided sales guidance for the year 2022. For the year, the company will continue to have sales and growth to remain its higher priority. The company will continue to expand its lab operations to include more tests as well.
The company expects that the increased sales are going to lead to a decrease in operating losses, and do estimate that the company has sufficient funds to complete the organic growth plan.
| 1st Jan change | Capi. | |
|---|---|---|
| +28.02% | 20.66M | |
| -31.90% | 9.59B | |
| -6.25% | 3.21B | |
| +25.95% | 2.92B | |
| -13.96% | 2.15B | |
| -16.83% | 1.79B | |
| +72.82% | 1.47B | |
| +29.17% | 770M | |
| -2.62% | 761M | |
| -26.33% | 548M |
SENZAGEN AB 
